anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To develop a tool for automated subtype classification and segmentation of intracranial hemorrhages (ICH) on CT scans of patients with traumatic brain injury (TBI). Furthermore, outcome prediction for patients can effectively facilitate patient management.
METHODS: This study presents a cascade framework for two-stage segmentation and multi-label classification. The hematoma region of interest (ROI) is localized, and then the ROI is cropped and resized to the original pixel size before being input into the model again to obtain the segmentation results. In multilabel classification, the mask obtained from automatic segmentation is superimposed onto the corresponding ROI and CT slices, respectively, to constitute the input image. Subsequently, the ROI image is employed as the local network input to obtain local features. Third, the CT image is utilized to construct a feature extraction network to obtain global features. Ultimately, the local and global features are fused dimensions in the pooling layer, and calculated to generate the final retrieval results. For the prediction of 14-day in-hospital mortality, automatically extracted hematoma subtype and volume features were integrated to enhance the widely used CRASH model.
RESULTS: The proposed segmentation method achieves the best estimates on the Dice similarity coefficient and Jaccard Similarity Index. The proposed multilabel classification method achieved an average accuracy of 95.91%. For mortality prediction, the best model achieved an average area under the receiver operating characteristic curve (AUC) of 0.91 by 5-fold cross-validation.
CONCLUSIONS: The proposed method enhances the precision of hematoma segmentation and subtype classification. In clinical settings, the method can streamline the evaluation of ICH for radiologists, and the automatically extracted features are anticipated to facilitate prognosis assessment.
OBJECTIVE: This study was conducted to assess the effect of osteochondroplasty on osteoarthritis (OA) prevention, comparing radiological evolution between identical hips from the same patient who had undergone unilateral surgery.
DESIGN: We retrospectively reviewed radiological evolution between hips with similar shape from the same patient who had undergone unilateral surgery. In all, 56 FAI patients (112 hips) with a mean age of 42.18 ± 9.16 years and had undergone unilateral arthroscopy treatment have been included. Four independent researchers measured Wiberg, Acetabular and Alpha angles, Extrusion index, and Tönnis classification preoperatively to verify that operated and non-operated hips had the same shape. OA evolution was assessed by joint space width (JSW) in 3 different articular points and Tönnis classification.
RESULTS: No preoperative anatomical differences were present between groups (P > 0.05). At the end of follow-up (31.9 months), a decrease of JSW in the 3 points measured was found in OP hips (OP vs. N-OP; P < 0.01). These results were correlated with changes in the proportion of patients who progressed to grade III in Tönnis classification (from 1.3% preoperative to 23.2% at the end of follow-up).
CONCLUSIONS: Osteochondroplasty and labrum procedures were not associated with OA prevention. The OP hips showed a faster OA degeneration, which was not seen in the N-OP. These results will encourage hip surgeons to perform further investigations to avoid the "Pandora's Box Opening Process."
This study seeks to develop and provide an initial test of a brief intervention to reduce alcohol use and sex risk behavior among Black and Latino men who have sex with men \[BLMSM\]. The study seeks to recruit BLMSM who are non-monogamous, not currently on pre-exposure prophylaxis \[PrEP\], have engaged in condomless anal intercourse over the past 6 months, who have engaged in heavy drinking defined as \>14 drinks per week or at least 1 heavy drinking episode (5+ drinks on a single occasion) in the past month. All participants will complete baseline measures about past month behavior and if eligible will be assigned to the intervention condition or an assessment only condition. The intervention consists of a single brief video-conferencing intervention coupled with 4 weeks of mobile-messaging related to individualized goals about alcohol use and sexual behavior. Follow-up assessments are scheduled for 4 weeks after baseline (upon completion of the mobile-messaging component of the intervention) and 2 months after baseline. Primary outcomes are feasibility and acceptability of the intervention and mobile-messaging components. Secondary outcomes are changes in frequency of condomless anal intercourse and heavy drinking episodes.
INTRODUCTION: Application of vapour ablation as a novel approach to lung volume reduction has positive effects in patients with severe emphysema. The BENTO study is a randomised, controlled, open, multicentre trial, to assess the effects of bronchoscopic thermal vapour ablation (BTVA) in the German healthcare system.
METHODS AND ANALYSIS: Patients with bilateral heterogeneous emphysema of the upper lobes in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3/4 will be enrolled in this trial and will receive either standard medical management alone (according to GOLD guidelines) or BTVA treatment with the InterVapor system together with standard medical management. Patients will be randomised in a 2:1 ratio (treatment group:control group). A total of 224 patients will be enrolled at 15 study sites. The primary endpoint is the change in patient-reported disease-specific quality of life, as measured by the St George's Respiratory Questionnaire for chronic obstructive pulmonary disease patients between randomisation and the 9-month follow-up visit. Secondary endpoints include adverse events, mortality, vital status, changes in lung function parameters, exercise capacity and other efficacy measures at 3, 9 and 12 months.The BENTO trial was commissioned by the German Federal Joint Committee, to demonstrate that this approach is an efficient and safe treatment option in the German healthcare system.
ETHICS AND DISSEMINATION: The protocol has been approved by the lead ethics committee in Germany (Ethics Committee of the Medical Faculty of Heidelberg) and until present also by the following ethics committees: Ethics Committee of the Medical Faculty of Duisburg-Essen, Ethics Committee of the Medical Faculty of Martin-Luther-University Halle-Wittenberg, Ethics Committee of the State Medical Association of Hessen, Ethics Commission of the State Office for Health and Social Affairs of the State of Berlin, Ethics Committee of the Medical Faculty of Greifswald. The results will be published in a peer-reviewed journal.
TRIAL REGISTRATION NUMBER: NCT05717192.
BACKGROUND: Cardiovascular discharge diagnoses may serve as endpoints in epidemiological studies if they have a high validity. Aim was to study if diagnoses-specific characteristics like type, sub-categories, and position of cardiovascular diagnoses affected diagnostic accuracy.
METHODS: Patients (n = 7,164) with a discharge diagnosis of acute myocardial infarction, heart failure or cerebrovascular disease were included. Data were presented as positive predictive values (PPV) and sensitivity.
RESULTS: PPV was high (≥88%) for acute myocardial infarction (n = 2,189) (except for outpatients). For heart failure (n = 4,026) PPV was 67% overall, but higher (>99%) when etiology or echocardiography was included. For hemorrhagic (n = 257) and ischemic (n = 1,034) strokes PPVs were 87% and 80%, respectively, with sensitivity of 79% and 75%. Transient ischemic attacks (n = 926) had PPV 56%, but sensitivity 86%. Primary diagnoses showed higher validity than subsequent diagnoses and inpatient diagnoses were more valid than outpatient diagnoses (except for transient ischemic attack). The diagnoses of acute myocardial infarction and heart failure where most valid when placed at cardiology units, while ischemic stroke when discharged from an internal medicine unit.
CONCLUSIONS: The diagnoses of acute myocardial infarction and stroke had excellent validity when placed during hospital stays. Similarly, heart failure diagnoses had excellent validity when echocardiography was performed before placing the diagnosis, while overall the diagnoses of heart failure and transient ischemic attack were less valid. In conclusion, the results indicate that cardiovascular diagnoses based on objective findings such as acute myocardial infarction and stroke have excellent validity and may be used as endpoints in clinical epidemiological studies with less rigid validation.
Cpds. of formula (I) and their salts are new. In (I) R is 2-7C alkyl or lower hydroxyalkyl. Pref. R is ethyl; 2-hydroxyethyl; n-hexyl; 4-hydroxybutyl; 2- or 3-hydroxypropyl, or S or R 3-hydroxybutyl. (I) are made from antibiotics X-14868A (i.e. the cpd. where R is H) by reaction with ROH in presence of ion-exchange resin, in acid form. The alcohol or diol may be used as solvent and is typically at room temp. The same method can also be used to prepare the known methyl ether. (I) are useful as antibiotics, anticoccidiosis and antimalarial agents, antiinflammatories and also for improving food utilisation in ruminants and pigs. The pref. daily dose is 0.03-0.075 mg/kg.
A composition for use in inducing or stimulating the growth of keratinous fibres, wherein the composition comprises pinene as an active ingredient is provided. Preferably at least 70% of the pinene is (-)-alpha pinene, more preferably the pinene is optically pure (-)-alpha pinene. The pinene may be present in an amount of between about 0.5% and about 10% (w/w). The keratinous fibre is preferably hair, wool, pelt, coat or fur. The composition may also be useful for increasing the density of the keratinous fibre. A method for inducing or stimulating growth of keratinous fibres comprising the step of administering to a subject an effective amount of a composition comprising pinene as an active ingredient and use of pinene for inducing or stimulating growth of keratinous fibres is also outlined.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that selectively invades superior and inferior motor neurons. Because there is no effective treatment, it is urgent to find the risk factors of ALS to guide the prevention and slow down the disease progression. In the early stage of the disease, the peripheral motor injury is more rapid and sensitive than the central response, which is an ideal window to observe the state of the disease. Protecting peripheral nerve integrity and maintaining its function can slow down the death of superior neurons, effectively relieve symptoms and prolong survival time, which has also been confirmed in patients with multiple stem cell-derived motor neurons and SOD1 G93A disease model mice. Reexamination of the role of peripheral motor nerve related factors in the development of ALS is of great significance for the study of disease mechanism, clinical classification, prognosis, evaluation of drug trial efficacy and individualized treatment plan. Previous studies have shown that NEFL gene, as the coding gene of light chain of neuron cytoskeleton, is closely related to axonal function, and its polymorphism is related to the occurrence and severity of axonal Charcot Marie Tooth disease. Exploring the role of similar peripheral nerve related genes in the progression of ALS will help us better understand the disease from the genetic level, establish an accurate and stable prognosis prediction model, and guide early treatment. This study will establish a comprehensive exon database of ALS patients, lay the foundation for screening the genes related to the occurrence and development of the disease, support the theory of ALS disease progression from peripheral to central, and reveal the correlation between the functional level of peripheral nerve and the prognosis of the disease at the gene level for the first time, and provide the basis for the mechanism research at the molecular level.
Described herein is a device, for insertion into a lumen of a human, the device comprising at least one cannabinoid. Optionally, the device is configured for insertion into a uterus of a female patient. The device is configured to gradually release the cannabinoid to the device's surroundings over time. Additionally, described herein are methods for treatment of a disease comprising administering to a patient in need thereof, a pharmaceutically acceptable amount of a cannabinoid via an intrauterine route. Optionally, the disease is endometrial cancer, uterine sarcoma, cervical cancer, Abnormal Pap Smears, Abnormal Uterine Bleeding, Endometriosis, Fibroids, Menopause, Ovarian Masses, Pelvic Pain, Polycystic Ovarian Syndrome, Sexually Transmitted Disease, Urinary Tract Infections, Vaginitis or ovarian cancer. Optionally, the disease is Lynch syndrome.
Data suggests that regions of the normal brain exposed to radiation doses that has otherwise been regarded as safe and not limited by current radiation treatment planning may contribute to the risk of late neurocognitive injury. Radiation dose-dependent subclinical vascular effects have been reported in irradiated normal brain tissue and have been hypothesized to be a potential mechanism of action. Direct neuronal injury is another potential mechanism of injury. 1)Estimate the degree of cognitive loss following RT. 2) Demonstrate evidence of radiation induced subclinical vascular and neuronal injury in adjacent brain regions receiving exit doses of radiation. Subjects will include patients with malignancies of the skull of the skull base or patients with low grade glioma who require radiotherapy. Baseline MRI imaging of the brain utilizing established techniques will be used to identify and characterize the regions of interest anatomically adjacent to the regions of intended high dose irradiation. The MRI data for the ROIs will be registered with the radiotherapy treatment planning CT in order to create a single volume of data where each voxel corresponds to a vector containing the multi-parametric information. Subsequent repeat MRI imaging will be at 1.5, 4.5, 12 and 24 months following completion of the radiotherapy for patients with low grade glioma and 1.5 and 12 months post radiotherapy for patients with malignancies involving the skull base. Both cohorts will repeat standard neurocognitive evaluation at 1.5, 4.5,12 and 24 months following completion of radiotherapy. Analysis: Neurocognitive domains will be evaluated at the designated time points.
ABSTRACT OF THE DISCLOSURE      The present invention relates to a novel antitumor antibiotic, BU3983T, and a process for preparing same by culturing  microorganisms  belonging  to  the  genus Actinomadura.  This compound demonstrates a high level of antitumor  activity  against  mouse  B16  melanoma.    An Actinomadura, Strain No. Q886-2, was isolated from a soil sample collected in Batangas, Luzon Island, Philippines. The new antitumor antibiotic BU-3983T was obtained by fermentation of this strain.  Based upon the morphology, cultural  and  physiological  characteristics  and  cell chemistry, the above-mentioned strain was identified as a species of Actinomadura, i.e., Actinomadura verrucosospora.
Patients assigned to this arm of the study will follow the standardized step-up approach to pain management per the hospital Evidenced Based Guideline (EBG). If analgesia is not obtained with first-line medications such as acetaminophen, the patient will be given the NSAID ketorolac intravenously every 6 hours at the standard weight-based dose throughout hospitalization. If the patient experiences continued pain, they (or their guardian/ caregiver) may request a rescue medication in the form of low-dose morphine (or an alternative opioid if allergic to morphine) at 0.025 mg/kg/dose every 4 hours.
Participants will complete baseline assessments and will be recontacted at 11 weeks to complete follow up assessments at week 12. Participants will receive a $25 gift card for each assessment ($50 total). If they would like to try the intervention at that time, we will send them Convoy-Pal equipment and materials. They will then have 12 weeks to use the tool.
BACKGROUND: Lipoabdominoplasty is an established technique, but outcomes of high lipoaspirate volumes in large series are lacking. The authors present the UK experience of high-volume, drainless lipoabdominoplasty using progressive deep tension sutures.
METHODS: A total of 286 consecutive patients at a single center underwent drainless lipoabdominoplasty with a lipoaspirate volume of 500 mL or greater between 2017 and 2023. Surgery was performed under total intravenous anesthesia with SAFELipo, MicroAire, and a superwet technique. Abdominoplasty was commenced through a low convex abdominal incision with multilayer rectus plication, and abdominal closure was undertaken with progressive tension sutures. Logistic regression was used to determine the relationship between lipoaspirate volume and 4 primary outcomes: all complications, delayed healing, seroma, and need for revision.
RESULTS: The mean lipoaspirate volume was 2392.4 mL (range, 500 to 5900 mL), and the abdominal tissue resection weight was 1392.0 g (range, 346 to 3802 g). One-third of patients had local complications (minor irregularities, 14.0%; abdominal scar problems, 12.9%; umbilical shape or scar, 4.5%; localized infection, 4.2%; and delayed healing, 3.8%). One patient (0.3%) had a small area of localized necrosis that was managed successfully by further tissue advancement. There was 1 abdominal hematoma and 2 systemic complications (venous thromboembolism, 0.3%; and drug-induced hepatitis, 0.3%). The seroma rate was 3.1%. A total of 16.0% of patients required revision under general anesthesia, and 6.6% under a local anesthetic. There was no significant relationship between the lipoaspirate volume and any of the 4 primary outcome measures.
CONCLUSIONS: High-volume liposuction can be performed safely simultaneously with abdominoplasty. The authors' complication rates are equivalent to or lower than other published data on lipoabdominoplasty, challenging current concepts in body sculpting.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.
Subjects with CLTI (Rutherford 4 or 5), who have undergone an endovascular procedure utilizing adjunctive therapies, other than balloon angioplasty alone, which are then followed by PTA and IVUS, and have an arterial dissection requiring repair. BTK subjects will have baseline lesions in the mid/distal popliteal, peroneal and/or tibial arteries.
1485268 Plant extracts S.E.R.T.O.G. SOC D'ETUDES DE RECHERCHES DE TRAVAUX D'ORGANISATION ET DE GESTION 4 June 1975 [4 June 1974] 24640/74 Heading ASB A pharmaceutical composition, with antiinflammatory, hormonal and muscular reactivation properties, contains as its active constituent an extract of a plant with an organic solvent, of the Meliaceae family of the genus Khaya selected from Khaya grandifolia, ivorensis or senegalensis. The extract is prepared by pre-drying and finely grinding the plant and extracting with an organic solvent selected from vegetable oils, e.g. palm or ground nut oil, hydrocarbons e.g. hexane chlorinated hydrocarbons e.g. chloroform or methylene chloride, ethers, alcohols or mixtures thereof.
A small group (1.3%) will develop a contracture post total knee arthroplasty. A second sample will be taken at the time of corrective surgery. The 2 samples will be compared for gene expression in the same subject. This group will also be compared to the main cohort for differential gene expression.
The present invention relates to a new galenic form of amino-4-hydroxy-2-benzoic acid, which is a potent non steroid anti-inflammatory substance known as 4-ASA. The tablets can be orally administered in order to provide for the controlled release of 4-ASA. The tablets are comprised of the active substance (4-ASA) which is distributed homogeneously in a hydrophilic matrix covered with a gastro-resistant coating. The gastro-resistant coating of the tablets impedes any direct contact between the active substance and the gastric mucosa thereby making it possible to avoid irritation of the gastric mucosa and to protect the active substance against gastric fluids. The gastro-resistant coating is selected among acrylic derivatives. The hydrophilic matrix, once removed of its coating as soon as it has reached the duodenum, behaves as a controlled release drug which releases regularly the active substance in the small intestine, the ileum, the colon and the ampulla recti. The hydrophilic polymers are selected among cellulose derivatives.
The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides the necessary information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through one or more metabolic pathways of interest. By this method, a comparison between subjects and control subjects reveals the effects of the chemical entity or entities on the biomarkers. This, in turn, allows for the identification of potential therapeutic uses or toxicities of the compound. Combinations of compounds can also be systematically evaluated for complementary, synergistic, or antagonistic actions on the metabolic pathways of interest, using the methods of the present invention as a strategy for identifying and confirming novel therapeutic or toxic combinations of compounds.
Control group, current hospital standard. AQUACEL is left in place for 7 days unless it becomes saturated over 50%, which requires a premature dressing change.
This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with low doses (LD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD) co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.